卒中是一种常见、严重的疾病,仅美国每年的新发病例就高达795 000例,并已成为全世界人类死亡和残疾的主要病因。10年前,重组型组织纤溶酶原激活剂(recombinanttissue plasminogen activator,rt-PA)被批准用于治疗急性缺血性卒中。rt-PA应用指南建议,应在卒中发病后3 h内静脉给予rt-PA,给药前应行头部CT检查,排除颅内出血。颅内出 Stroke is a common and serious disease that reaches as many as 795,000 new cases a year in the United States alone and has become the leading cause of death and disability worldwide. Ten years ago, recombinant tissue plasminogen activator (rt-PA) was approved for the treatment of acute ischemic stroke. rt-PA application guidelines suggest that rt-PA should be given intravenously within 3 h after onset of stroke, head CT should be performed prior to administration to exclude intracranial hemorrhage. Intracranial out